gusperimus
Small moleculeexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 1999 (NCT00001984)
Timeline
Indications
Mechanism of action
- Putative heat shock 70 kDa protein 7INHIBITOR
HSPA7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cl.Cl.Cl.N=C(N)NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCCN- Mol. weight
- 496.91 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2356648 ↗
- ChEMBLCHEMBL406117 ↗
- ChEMBLCHEMBL1996913 ↗
Also known as
- 15-deoxyspergualin
- 15-deoxyspergualin trihydrochloride
- 15-deoxyspergualin trihydrochloride
- 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione
- bms-181173
- bms-181173
- bmy-42215-1
- bmy-42215-1
- deoxyspergualin
- deoxyspergualin
- deoxyspergualin
- deoxyspergualin
- deoxyspergualin
- deoxyspergualin
- deoxyspergualin
- (+/-)-deoxyspergualin
- gusperimus
- gusperimus
- gusperimus
- gusperimus
- gusperimus
- gusperimus
- gusperimus
- gusperimus hcl
- gusperimus hcl
- gusperimus hcl
- gusperimus hydrochloride
- gusperimus, (+-)-isomer
- gusperimus trihydrochloride
- gusperimus trihydrochloride
- gusperimus trihydrochloride
- gusperimus trihydrochloride
- heptanamide, 7-((aminoiminomethyl)amino)-n-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-
- nkt-01
- nkt-01
- nkt-01
- nkt-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01446211 | Phase 3 | Nov 1, 2011 | Nordic Pharma Group, University of Cambridge |
| NCT01052259 | N/A | Jun 1, 2009 | Nippon Kayaku Co.,Ltd., Sapporo City General Hospital |
| NCT00434850 | Phase 2 | Oct 1, 2006 | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Northwestern University, University of California, San Francisco, University of Minnesota |
| NCT00530075 | Phase 2 | Dec 1, 2003 | Nippon Kayaku Co.,Ltd., University of Cambridge |
| NCT00709722 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2003 | Nippon Kayaku Co.,Ltd., University of Heidelberg |
| NCT00001984 | Phase 2 | Nov 1, 1999 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nippon Kayaku Co.,Ltd. | For profit | 3 | 3 | 2 | 2003 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 2 | 1 | 1 | 1999 |
| University of Cambridge | Academic/Hospital | 2 | 0 | 2 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2006 |
| Nordic Pharma Group | For profit | 1 | 1 | 1 | 2011 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Sapporo City General Hospital | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2006 |
10 organizations
Page 1 / 1